Recent Price and Market Performance
On the latest trading day, Tarsons Products Ltd’s stock price fell by 3.21%, markedly underperforming the Sensex’s 1.02% decline. Over the past week, the stock has lost 8.47%, compared to a modest 1.21% drop in the Sensex. The one-month performance shows a 6.84% decrease against a 1.11% gain in the benchmark index. This downward trend extends over three months with a 7.33% loss versus the Sensex’s 2.90% decline.
Year-to-date, the stock has declined by 20.61%, significantly lagging the Sensex’s 3.26% fall. Over the last year, the stock’s performance has been particularly weak, registering a 37.51% loss while the Sensex gained 10.73%. The three-year picture is even more stark, with Tarsons Products Ltd down 69.53% compared to a 38.64% rise in the Sensex. Notably, the stock has delivered no returns over five and ten years, while the Sensex has appreciated by 62.35% and 257.06% respectively.
Tarsons Products is currently trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — underscoring the sustained bearish momentum. The stock has also underperformed its healthcare services sector by 1.05% on the day.
Financial Metrics and Profitability Trends
The company’s financial indicators reveal a challenging environment. Operating profit has contracted at an annualised rate of 18.84% over the past five years, reflecting persistent pressure on earnings. The latest six-month period saw a 40.41% decline in profit after tax (PAT), which stood at ₹9.27 crores. This negative earnings trajectory has persisted for three consecutive quarters.
Return on Capital Employed (ROCE) for the half-year is at a low 6.69%, indicating limited efficiency in generating returns from capital invested. The debt-to-equity ratio has increased to 0.41 times, the highest in recent periods, though still moderate by industry standards. The company’s average debt-to-equity ratio remains low at 0.35 times, suggesting a conservative capital structure despite recent upticks.
Under the radar no more! This Large Cap from Cement is emerging from turnaround with solid fundamentals intact. Discover it while it's still relatively hidden!
- - Hidden turnaround gem
- - Solid fundamentals confirmed
- - Large Cap opportunity
Institutional Investor Activity
Institutional participation in Tarsons Products Ltd has diminished, with a 3.44% reduction in stake over the previous quarter. Currently, institutional investors hold a mere 2.47% of the company’s shares. This decline in institutional ownership may reflect a reassessment of the company’s fundamentals by investors with greater analytical resources.
Valuation and Comparative Analysis
Despite the weak performance, the company’s valuation metrics suggest some degree of attractiveness relative to peers. The ROCE of 3.9 and an enterprise value to capital employed ratio of 1.4 indicate that the stock is trading at a discount compared to historical averages within the sector. However, this valuation discount accompanies a backdrop of declining profitability, with profits falling by 30% over the past year.
Tarsons Products Ltd’s market capitalisation grade stands at 4, reflecting its size and liquidity profile within the healthcare services sector. The company’s Mojo Score is 28.0, with a Mojo Grade of Strong Sell as of 23 Feb 2026, downgraded from Sell. This rating reflects the cumulative impact of deteriorating financial performance and market sentiment.
Holding Tarsons Products Ltd from Healthcare Services? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Long-Term Performance and Sector Context
Over the last three years, Tarsons Products Ltd has consistently underperformed the BSE500 index and its healthcare services sector peers. The stock’s negative returns contrast sharply with the broader market’s positive trajectory, highlighting the company’s relative weakness. The absence of any gains over five and ten years further emphasises the prolonged challenges faced by the company.
While the company maintains a relatively low debt burden, its profitability metrics and market valuation reflect the impact of sustained earnings declines. The stock’s proximity to its 52-week low and its position well below all major moving averages underscore the prevailing bearish sentiment.
Summary of Key Metrics
To summarise, Tarsons Products Ltd’s key financial and market indicators as of 24 Feb 2026 are:
- Stock price near 52-week low: ₹188.05 (0.45% away)
- Day change: -3.21%
- One-year return: -37.51%
- Three-year return: -69.53%
- Operating profit CAGR (5 years): -18.84%
- PAT decline (latest six months): -40.41%
- ROCE (HY): 6.69%
- Debt-to-equity ratio (HY): 0.41 times
- Institutional ownership: 2.47%, down 3.44% QoQ
- Mojo Score: 28.0 (Strong Sell, downgraded from Sell)
These figures collectively illustrate the severity of the stock’s decline and the challenges faced by Tarsons Products Ltd within the healthcare services sector.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
